Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...

Eli Lilly anticipates regulatory approval for its weight-loss drug Zepbound in Japan by mid-2025, boosting its global ...

Peptide companies' are creating knock-off versions of these drugs that have not been approved by the FDA and contain ...

The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related ...

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

All the state leaders should be getting their people out … to watch for ballot stuffing,” wrote the leader of the American ...

Lilly has earmarked $200 million for the upgrade, a company spokesperson confirmed to Fierce Pharma. The new project will ...

GLP-1 drugs such as Wegovy and Ozempic (semaglutide) and Zepbound (tirzepatide) may offer benefits that extend beyond aiding ...

Zealand Pharma CEO Adam Steensberg said Friday that the company is working on a next-generation weight loss drug that’s ...

If Medicare were to start covering popular weight loss drugs such as Wegovy and Zepbound, it could increase federal spending ...

PS makes wellness more accessible through real-life stories, first-person perspectives, and expert-backed information. Our ...